NCT00679146已完成3 期
Efficacy and Safety of a Fixed Combination (Thiocolchicoside 8 mg + Ketoprofen 100 mg ) Compared to Thiocolchicoside 8 mg Administered Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 334
- 试验地点
- 1
- 主要终点
- Average pain within the last 24 hours (VAS)
研究概览
简要总结
Primary Objective :
To demonstrate the superiority of the oral fixed - combination of a muscle relaxant, thiocolchicoside (TCC) to a non steroidal anti-inflammatory drug, ketoprofen, over oral TCC, on average pain within the last 24 hours in adults suffering from acute non specific low back pain with an episode of recent onset
Secondary Objective :
To compare the safety of the oral combination to that of oral TCC alone
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non specific low back pain with an acute episode of recent onset (<48 hours) defined by average pain within the last 24 hours equal or more than 50 mm on the Visual Analogue Scale (VAS)
- •Low back pain of diagnosis category 1 (low back pain radiating no farther than the intergluteal fold) or 2 (low back pain radiating no farther than the knee), as defined by the International Paris Task Force on Back Pain
排除标准
- •Exclusion criteria related to study methodology:
- •Low back pain due to vertebral collapse or of no mechanical origin (suspected by history taking and physical examination), such as neoplasm, infection or inflammatory disorders,
- •Low back pain of diagnosis category 3 (low back pain radiating beyond the knee, with no neurologic signs) or 4 (low back pain radiating to a precise and entire leg dermatome, with or without neurologic signs), as defined by the International Paris Task Force on Back Pain
- •History of inflammatory arthritis of large joints,
- •History of seizure disorders,
- •History of malignant tumour,
- •Treatment with steroidal agents (including aspirin) during the two days prior to prospective inclusion, prolonged used of corticosteroids,
- •Treatment with NSAIDs or muscle relaxant or opioid analgesics within 3 days of admission,
- •Psychiatric or mental diseases,
- •Immunosuppression, HIV,
- •Inclusion in another study in the past six months or previous inclusion in this study,
- •History of alcohol, drugs or narcotics abuse
- •Recent history of violent trauma,
- •Constant progressive, non mechanical pain (no relief with bed rest),
- •Thoracic pain,
- •Patient systemically unwell,
- •Unexplained weight loss,
- •Widespread neurological symptoms (including cauda equine syndrome),
- •Structural deformity
- •Clinical significant renal dysfunction defined by Creatinine > 1.5 UNL,
- •Clinically significant hepatic dysfunction defined by:
- •Total Bilirubin > 2 UNL
- •SGOT (AST) > 1.5 UNL
- •SGPT (ALAT) > 1.5 UNL
- •Alkaline Phosphatase > 1.5 UNL
- •Patients who have received other therapy (physiotherapy, physical manipulations, invasive intervention, acupuncture therapy...) within the last 48 hours.
- •Exclusion criteria related to trial drugs:
- •Pregnancy, breast feeding or women of childbearing potential not using efficient contraception. Patient with Intra Uterine Device should use another form of contraception as the efficacy of the IUD may be reduced by ketoprofen.
- •Exclusion criteria related to thiocolchicoside:
- •Known or suspected hypersensitivity to thiocolchicoside
- •Exclusion criteria related to ketoprofen:
- •Uncontrolled heart failure,
- •Arterial Hypertension (SBP>140 mmHg or DBP >90 mmHg),
- •Stroke or myocardial infarction in the past,
- •Myasthenia,
- •History of active peptic ulcer or gastrointestinal (GI) bleeding, history of gastric pain with NSAIDs,
- •History of NSAID/aspirin-induced asthma,
- •Known or suspected hypersensitivity to ketoprofen.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Active Comparator
1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
干预措施: Thiocolchicoside+Ketoprofen (Drug)
2
Active Comparator
2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
干预措施: Thiocolchicoside (Drug)
结局指标
主要结局
Average pain within the last 24 hours (VAS)
时间窗: at D3 visit
次要结局
- Average pain within the last 24 hours (VAS)(at D7 visit)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous PatientsOpen Angle GlaucomaOcular HypertensionNCT02278614Laboratoires Thea242
已完成
3 期
Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu SyndromeFluNCT01389518Hospital de Clinicas de Porto Alegre146
已完成
3 期
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.Essential HypertensionNCT05288400Servier150
已完成
4 期
Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous InsufficiencyChronic Venous InsufficiencyNCT01848210Takeda829
已完成
3 期
Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in HypertensionHypertensionNCT05820880Institut de Recherches Internationales Servier532